Alliancebernstein L.P. lowered its position in Novavax, Inc. (NASDAQ:NVAX) by 16.3% during the first quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 304,501 shares of the biopharmaceutical company’s stock after selling 59,200 shares during the period. Alliancebernstein L.P.’s holdings in Novavax were worth $390,000 as of its most recent SEC filing.

Other institutional investors have also bought and sold shares of the company. Norges Bank acquired a new position in Novavax during the fourth quarter worth approximately $3,300,000. JPMorgan Chase & Co. boosted its position in Novavax by 41.9% in the first quarter. JPMorgan Chase & Co. now owns 3,708,105 shares of the biopharmaceutical company’s stock worth $4,746,000 after buying an additional 1,095,388 shares during the last quarter. Canada Pension Plan Investment Board acquired a new position in Novavax during the first quarter worth approximately $157,000. Renaissance Technologies LLC acquired a new position in Novavax during the fourth quarter worth approximately $544,000. Finally, Bank of New York Mellon Corp boosted its position in Novavax by 0.9% in the first quarter. Bank of New York Mellon Corp now owns 1,215,100 shares of the biopharmaceutical company’s stock worth $1,555,000 after buying an additional 10,347 shares during the last quarter. Institutional investors and hedge funds own 50.16% of the company’s stock.

Shares of Novavax, Inc. (NASDAQ:NVAX) traded up 1.8673% on Friday, reaching $0.9983. 3,688,982 shares of the company’s stock traded hands. The firm’s market cap is $289.41 million. Novavax, Inc. has a one year low of $0.73 and a one year high of $8.49. The company’s 50-day moving average price is $1.15 and its 200 day moving average price is $1.15.

Novavax (NASDAQ:NVAX) last announced its quarterly earnings results on Tuesday, August 8th. The biopharmaceutical company reported ($0.16) EPS for the quarter, meeting the Thomson Reuters’ consensus estimate of ($0.16). Novavax had a negative net margin of 1,006.00% and a negative return on equity of 787.38%. The firm had revenue of $6.70 million during the quarter, compared to the consensus estimate of $6.15 million. During the same period last year, the firm earned ($0.29) EPS. The business’s quarterly revenue was up 168.0% compared to the same quarter last year. On average, equities analysts forecast that Novavax, Inc. will post ($0.62) EPS for the current fiscal year.

TRADEMARK VIOLATION NOTICE: “Novavax, Inc. (NASDAQ:NVAX) Shares Sold by Alliancebernstein L.P.” was originally published by Watch List News and is the sole property of of Watch List News. If you are reading this piece on another site, it was illegally stolen and reposted in violation of international copyright and trademark law. The legal version of this piece can be viewed at https://www.watchlistnews.com/novavax-inc-nasdaqnvax-shares-sold-by-alliancebernstein-l-p/1478846.html.

A number of equities research analysts have recently issued reports on NVAX shares. Cantor Fitzgerald restated a “hold” rating and set a $2.00 price objective on shares of Novavax in a report on Friday, July 21st. BidaskClub cut Novavax from a “hold” rating to a “sell” rating in a report on Wednesday, July 19th. ValuEngine cut Novavax from a “sell” rating to a “strong sell” rating in a report on Friday, June 2nd. Chardan Capital restated a “neutral” rating and set a $1.50 price objective on shares of Novavax in a report on Thursday, July 27th. Finally, Zacks Investment Research upgraded Novavax from a “hold” rating to a “buy” rating and set a $1.25 price objective for the company in a report on Saturday, June 10th. Two analysts have rated the stock with a sell rating, seven have given a hold rating, three have issued a buy rating and one has assigned a strong buy rating to the company’s stock. Novavax presently has a consensus rating of “Hold” and an average price target of $5.24.

About Novavax

Novavax, Inc is a clinical-stage vaccine company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants. The Company operates through developing recombinant vaccines segment. The Company, through its recombinant nanoparticle vaccine technology, produces vaccine candidates to respond to both known and newly emerging diseases.

Want to see what other hedge funds are holding NVAX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Novavax, Inc. (NASDAQ:NVAX).

Institutional Ownership by Quarter for Novavax (NASDAQ:NVAX)

Receive News & Ratings for Novavax Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novavax Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.